Learn more about PCSK9 inhibition with PRALUENT from a PRALUENT Field Representative
Contact a rep
See if patients in your practice are right for PRALUENT
Find out now
THE POWER OF PRALUENT
Get more information on the efficacy of PRALUENT in clinical trials
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2017. doi: 10.1016/j.jacc.2017.07.745.
PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.